GMAB · Nasdaq, OTC · CIK 0001434265

GENMAB A/S

GENMAB A/S’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 23, 2026. Its EDGAR record lists 4 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2024
—
Net income, FY2024
DKK 7.8B
Form 4 filings on record, past 12 months
4

Company overview

Legal name (as filed)
GENMAB A/S
Tickers
GMAB, GNMSF
SEC Central Index Key (CIK)
0001434265
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
1253 COPENHAGEN K, Denmark
State or country of incorporation
—
Fiscal year ends
—
SEC filer category
Large accelerated filer
Position in SEC ticker list
#526 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from GENMAB A/S’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in DKK; the fiscal year is named for the calendar year in which it ends.

Revenue
DKK 2.4BFY2017DKK 3.0BFY2018DKK 5.4BFY2019n/aFY2023n/aFY2024
Net income
DKK 1.1BFY2017DKK 1.5BFY2018DKK 2.2BFY2019DKK 4.4BFY2023DKK 7.8BFY2024
GMAB annual results
ItemFY2017
ended Dec 31, 2017		FY2018
ended Dec 31, 2018		FY2019
ended Dec 31, 2019		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024
RevenueDKK 2.4BDKK 3.0BDKK 5.4B——
Net incomeDKK 1.1BDKK 1.5BDKK 2.2BDKK 4.4BDKK 7.8B
Diluted EPSDKK 17.77DKK 23.73DKK 34.03DKK 66.02DKK 121.36
Total assets—DKK 8.5BDKK 15.1BDKK 35.3BDKK 45.8B
Cash and equivalentsDKK 1.3BDKK 533.0MDKK 2.9B——

XBRL tags used: revenue = Revenue; netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = Cash. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

GMAB latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 17, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Oct 23, 20266-KReport of a foreign private issuer· period Oct 23, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about GENMAB A/S, by form type:

6-K ×37SCHEDULE 13G/A ×2SCHEDULE 13G ×1
GMAB recent filings
FiledFormWhat it isOriginal
Oct 23, 20266-KReport of a foreign private issuer· period Oct 23, 2026Document · Index
Oct 13, 20266-KReport of a foreign private issuer· period Oct 13, 2026Document · Index
Oct 7, 20266-KReport of a foreign private issuer· period Oct 7, 2026Document · Index
Oct 5, 20266-KReport of a foreign private issuer· period Oct 5, 2026Document · Index
Oct 5, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Oct 2, 20266-KReport of a foreign private issuer· period Oct 2, 2026Document · Index
Sep 29, 20266-KReport of a foreign private issuer· period Sep 29, 2026Document · Index
Sep 24, 20266-KReport of a foreign private issuer· period Sep 24, 2026Document · Index
Sep 9, 20266-KReport of a foreign private issuer· period Sep 9, 2026Document · Index
Sep 9, 20266-KReport of a foreign private issuer· period Sep 8, 2026Document · Index
Sep 8, 20266-KReport of a foreign private issuer· period Sep 8, 2026Document · Index
Aug 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 12, 20266-KReport of a foreign private issuer· period Aug 12, 2026Document · Index
Aug 11, 20266-KReport of a foreign private issuer· period Aug 11, 2026Document · Index
Aug 6, 20266-KReport of a foreign private issuer· period Jun 30, 2026Document · Index
Jul 15, 20266-KReport of a foreign private issuer· period Jul 15, 2026Document · Index
Jun 29, 20266-KReport of a foreign private issuer· period Jun 29, 2026Document · Index
Jun 17, 20266-KReport of a foreign private issuer· period Jun 17, 2026Document · Index
Jun 16, 20266-KReport of a foreign private issuer· period Jun 16, 2026Document · Index
Jun 15, 20266-KReport of a foreign private issuer· period Jun 15, 2026Document · Index
Jun 15, 20266-KReport of a foreign private issuer· period Jun 15, 2026Document · Index
Jun 11, 20266-KReport of a foreign private issuer· period Jun 11, 2026Document · Index
May 29, 20266-KReport of a foreign private issuer· period May 29, 2026Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 13, 20266-KReport of a foreign private issuer· period May 13, 2026Document · Index
May 12, 20266-KReport of a foreign private issuer· period May 12, 2026Document · Index
May 8, 20266-KReport of a foreign private issuer· period May 8, 2026Document · Index
May 7, 20266-KReport of a foreign private issuer· period May 7, 2026Document · Index
Apr 17, 20266-KReport of a foreign private issuer· period Apr 17, 2026Document · Index
Apr 17, 20266-KReport of a foreign private issuer· period Apr 17, 2026Document · Index
Apr 14, 20266-KReport of a foreign private issuer· period Apr 14, 2026Document · Index
Apr 14, 20266-KReport of a foreign private issuer· period Apr 14, 2026Document · Index
Apr 1, 20266-KReport of a foreign private issuer· period Apr 1, 2026Document · Index
Apr 1, 20266-KReport of a foreign private issuer· period Apr 1, 2026Document · Index
Mar 30, 20266-KReport of a foreign private issuer· period Mar 30, 2026Document · Index
Mar 23, 20266-KReport of a foreign private issuer· period Mar 23, 2026Document · Index
Mar 19, 20266-KReport of a foreign private issuer· period Mar 19, 2026Document · Index
Mar 19, 20266-KReport of a foreign private issuer· period Mar 19, 2026Document · Index
Mar 16, 20266-KReport of a foreign private issuer· period Mar 16, 2026Document · Index
Mar 9, 20266-KReport of a foreign private issuer· period Mar 9, 2026Document · Index

Insider filing activity

4 Form 4 filings appear in GENMAB A/S’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001434265 and XBRL company facts. GENMAB A/S on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.